PDCD1 and cancer: For patients with mismatch repair deficient stage II or III rectal cancer, PD-1 antibody (dostarlimab) monotherapy exerted a complete clinical response [4], underscoring the remarkable potential of immune checkpoint inhibitors for certain types/subtypes of cancer.